2. Search Result
Search Result
Results for "

receptor for advanced glycation end products (RAGE)

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-50682
    Azeliragon
    10+ Cited Publications

    TTP488; PF-04494700

    		 Amyloid-β Neurological Disease Cancer
    Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon
  • HY-147329
    RAGE 229

    		Transmembrane Glycoprotein Metabolic Disease
    RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1) .
    RAGE 229
  • HY-W585874
    Nε-(Carboxyethyl)lysine

    		EAAT Apoptosis Neurological Disease Metabolic Disease
    Nε-(Carboxyethyl) lysine is an advanced glycation end product (AGE). Nε-(Carboxyethyl) lysine induces cross-linking between proteins, thereby affecting protein structure and function and causing protein denaturation. Nε-(Carboxyethyl) lysine binds to the RAGE receptor, affects cell signal transduction, and regulates processes such as inflammatory responses, cell proliferation, and apoptosis. Nε-(Carboxyethyl) lysine affects glutamate transporters, reduces glutamate uptake and S100β protein secretion, influences neurotransmission in the nervous system, and exhibits diabetes-related neurotoxicity .
    Nε-(Carboxyethyl)lysine
  • HY-50682S
    Azeliragon-d9

    TTP488-d9; PF-04494700-d9

    		 Isotope-Labeled Compounds Amyloid-β Neurological Disease Endocrinology
    Azeliragon-d9 (TTP488-d9) is the deuterium labeled Azeliragon (HY-50682). Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon-d9
  • HY-50682A
    Azeliragon dihydrochloride

    TTP488 dihydrochloride; PF-04494700 dihydrochloride

    		 Amyloid-β Neurological Disease Cancer
    Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB) .
    Azeliragon dihydrochloride
  • HY-50682R
    Azeliragon (Standard)

    TTP488 (Standard); PF-04494700 (Standard)

    		 Amyloid-β Reference Standards Neurological Disease Cancer
    Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon (Standard)
  • HY-156049
    MG-H1

    		Amyloid-β Metabolic Disease
    MG-H1 is a receptor of advanced glycation end products (RAGE) ligand with a Kd of 4.12 nM. MG-H1 can bind to human umbilical vein endothelial cell. MG-H1 can be used for research of diabetes .
    MG-H1

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: